Therapeutic potential of statins in Alzheimer's disease

Journal of the Neurological Sciences

Volumn 283, Issue 1-2, 2009, Pages 230-234

  Kandiah, Nagaendran ^a   Feldman, Howard H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Cholesterol; Statins

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID; BRAIN; CEREBROVASCULAR DISORDERS; CHOLESTEROL; COGNITION DISORDERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, NEUROLOGICAL; NEUROFIBRILLARY TANGLES; NEUROIMMUNOMODULATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 67650128395     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.02.352     Document Type: Article

References (54)

1. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., and Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1 1 (Jan 1991) 103-116
2. Reid P.C., Urano Y., Kodama T., and Hamakubo T. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11 3 (May 2007) 383-392
3. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., and Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 277 (1997) 813-817
4. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (Nov 2000 11) 1627-1631
5. Hajjar I., Schumpert J., Hirth V., Wieland D., and Eleazer G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57 7 (Jul 2002) M414-M418
6. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59 2 (Feb 2002) 223-227
7. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62 2 (Feb 2005) 217-224
8. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.K., Newman A.B., et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62 7 (Jul 2005) 1047-1051
9. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 9 (Nov 9 2004) 1624-1628
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (Jul 6 2002) 7-22
11. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 9346 (Nov 23 2002) 1623-1630
12. Yaffe K., Barrett-Connor E., Lin F., and Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59 (2002) 378-384
13. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 5 (May 2005) 753-757
14. Pfrieger F.W. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 60 6 (Jun 2003) 1158-1171
15. Heverin M., Bogdanovic N., Lutjohann D., Bayer T., Pikuleva I., Bretillon L., et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 45 1 (Jan 2004) 186-193
16. Leoni V., Masterman T., Patel P., Meaney S., Diczfalusy U., and Bjorkhem I. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J Lipid Res 44 4 (Apr 2003) 793-799
17. Mathews C.K. Biochemistry. 3rd ed. (2000), Wesley Longman, Inc., San Francisco
18. Jurevics H., and Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64 2 (Feb 1995) 895-901
19. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9 3 (Mar 2003) 94-101
20. Bogdanovic N., Bretillon L., Lund E.G., Diczfalusy U., Lannfelt L., Winblad B., et al. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314 1-2 (Nov 13 2001) 45-48
21. Combarros O., Infante J., Llorca J., and Berciano J. Genetic association of CYP46 and risk for Alzheimer's disease. Dement Geriatr Cogn Disord 18 3-4 (2004) 257-260
22. Kolsch H., Heun R., Kerksiek A., Bergmann K.V., Maier W., and Lutjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci Lett 368 3 (Sep 30 2004) 303-308
23. Liu L., Bortnick A.E., Nickel M., Dhanasekaran P., Subbaiah P.V., Lund-Katz S., et al. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J Biol Chem 278 44 (Oct 31 2003) 42976-42984
24. Koldamova R.P., Lefterov I.M., Ikonomovic M.D., Skoko J., Lefterov P.I., Isanski B.A., et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem 278 15 (Apr 11 2003) 13244-13256
25. Moya K.L., Benowitz L.I., Schneider G.E., and Allinquant B. The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. Dev Biol 161 2 (Feb 1994) 597-603
26. Zheng H., and Koo E.H. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1 (2006) 5
27. Wahrle S., Das P., Nyborg A.C., McLendon C., Shoji M., Kawarabayashi T., et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 9 1 (Feb 2002) 11-23
28. Bodovitz S., and Klein W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271 8 (Feb 23 1996) 4436-4440
29. Kojro E., Gimpl G., Lammich S., Marz W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 98 10 (May 8 2001) 5815-5820
30. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat Neurosci 6 4 (Apr 2003) 345-351
31. McLaurin J., Darabie A.A., and Morrison M.R. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis. Pharmacopsychiatry 36 Suppl 2 (Sep 2003) S130-S135
32. Girardot N., Allinquant B., Langui D., Laquerriere A., Dubois B., Hauw J.J., et al. Accumulation of flotillin-1 in tangle-bearing neurones of Alzheimer's disease. Neuropathol Appl Neurobiol 29 5 (Oct 2003) 451-461
33. Lutjohann D., Breuer O., Ahlborg G., Nennesmo I., Siden A., Diczfalusy U., et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 93 18 (Sep 3 1996) 9799-9804
34. Famer D., Meaney S., Mousavi M., Nordberg A., Bjorkhem I., and Crisby M. Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun 359 1 (Jul 20 2007) 46-50
35. Sadowski M., Pankiewicz J., Scholtzova H., Li Y.S., Quartermain D., Duff K., et al. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res 29 6 (Jun 2004) 1257-1266
36. Breteler M.M. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 903 (Apr 2000) 457-465
37. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47 6 (Jun 2000) 739-747
38. Li G., Larson E.B., Sonnen J.A., Shofer J.B., Petrie E.C., Schantz A., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69 9 (Aug 28 2007) 878-885
39. Buxbaum J.D., Geoghagen N.S., and Friedhoff L.T. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis 3 2 (Apr 2001) 221-229
40. Kirsch C., Eckert G.P., and Mueller W.E. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65 5 (Mar 1 2003) 843-856
41. Locatelli S., Lutjohann D., Schmidt H.H., Otto C., Beisiegel U., and von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59 2 (Feb 2002) 213-216
42. Vega G.L., Weiner M.F., Lipton A.M., von Bergmann K., Lutjohann D., Moore C., et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60 4 (Apr 2003) 510-515
43. Hess D.C., Demchuk A.M., Brass L.M., and Yatsu F.M. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology 54 4 (Feb 22 2000) 790-796
44. Kaesemeyer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33 1 (Jan 1999) 234-241
45. Davignon J., and Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10 6 (Dec 1999) 543-559
46. Jagust W.J., Eberling J.L., Reed B.R., Mathis C.A., and Budinger T.F. Clinical studies of cerebral blood flow in Alzheimer's disease. Ann N Y Acad Sci 826 (Sep 26 1997) 254-262
47. Dahiyat M., Cumming A., Harrington C., Wischik C., Xuereb J., Corrigan F., et al. Association between Alzheimer's disease and the NOS3 gene. Ann Neurol 46 4 (Oct 1999) 664-667
48. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 6 (Aug 10 2006) 549-559
49. Shobab L.A., Hsiung G.Y., and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol 4 12 (Dec 2005) 841-852
50. Vergouwen M.D., de Hann R.J., Vermeulen M., and Roos Y.B. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 39 2 (2008) 497-502
51. Sturgeon J.D., Folsom A.R., Longstreth Jr. W.T., Shahar E., Rosamond W.D., and Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 38 10 (Oct 2007) 2718-2725
52. Sudlow C., Martinez Gonzalez N.A., Kim J., and Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke 37 2 (Feb 2006) 364-370
53. Michikawa M., and Yanagisawa K. Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J Neurosci Res 54 1 (Oct 1 1998) 58-67
54. Meske V., Albert F., Richter D., Schwarze J., and Ohm T.G. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci 17 1 (Jan 2003) 93-102